78 results on '"Lofland, Jennifer"'
Search Results
2. Systemic Lupus Erythematosus Symptom Clusters and Their Association With Patient‐Reported Outcomes and Treatment: Analysis of Real‐World Data
3. Update on prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016
4. Inadequate Disease Control, Treatment Dissatisfaction, and Quality-of-Life Impairments Among US Patients Receiving Topical Therapy for Atopic Dermatitis
5. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
6. Real-world impact of flaring on patient-reported outcomes and healthcare resource utilisation in systemic lupus erythematosus
7. Update on Prevalence of Diagnosed Systemic Lupus Erythematosus (SLE) by Major Health Insurance Types in the US
8. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus
9. Opioid Use in Patients With Inflammatory Bowel Disease
10. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States
11. The role of the pharmacist in disease management
12. Pharmacy practice and health policy within the U.S.
13. FRI0201 REAL WORLD MEDICATION USE IN INCIDENT SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS PATIENTS
14. FRI0178 CLUSTER PROFILING OF PATIENTS IN A REAL-WORLD DATA SET WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND THEIR ASSOCIATED TREATMENTS
15. FRI0256 ASSESSING THE PREVALENCE AND USE OF VALIDATED SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY METRICS IN REAL WORLD PRACTICE
16. AB0486 LACK OF CONSISTENT STANDARD OF CARE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN REAL WORLD
17. Sa1811 - Opioid use in Patients with Inflammatory Bowel Disease
18. Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs
19. Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis
20. An Assessment of the AGA and CCFA Quality Indicators in a Sample of Patients Diagnosed with Inflammatory Bowel Disease
21. Prescribing Patterns of Intravenous Golimumab for Rheumatoid Arthritis
22. The Employee Absenteeism Costs of Rheumatoid Arthritis
23. Novel Statistical Approach to Determine Inflammatory Bowel Disease: Patients’ Perspectives on Shared Decision Making
24. Gastroenterologists’ Views of Shared Decision Making for Patients with Inflammatory Bowel Disease
25. Variations in care: a retrospective database analysis of healthcare utilization patterns for patients with inflammatory bowel disease
26. Adjusting for comorbidities in cost of illness studies
27. Inflammatory Bowel Disease Quality Measure Results in a Large National Plan Dataset
28. Su1316 Effects of Patient Annual Adherence of Biologics on Healthcare Resource Utilization for Patients With Inflammatory Bowel Disease
29. P-058 Crohn’s Disease Patients with Early Biologic Treatment Versus Late Biologic Treatment
30. P-041 Cost per Clinical Response, Clinical Remission, and Mucosal Healing of Adalimumab, Golimumab, and Infliximab Among Patients with Ulcerative Colitis (UC)
31. P-060 Cost Per Clinical Response, Clinical Remission, and Mucosal Healing of Golimumab Among Patients with Ulcerative Colitis
32. Comparative Efficacy of Adalimumab, Golimumab, and Infliximab in the Treatment of Patients with Ulcerative Colitis: An Induction Analysis
33. Cost Per Clinical Remission and Clinical Response of Adalimumab, Golimumab, and Infliximab in the Treatment of Patients with Ulcerative Colitis: An Induction Analysis
34. Mo1362 Geographic Variation in Care of Patients With Inflammatory Bowel Disease Suggests Unequal Quality of Care in the United States
35. The Employee Absenteeism Costs of Inflammatory Bowel Disease
36. Cost-per-remission analysis of infliximab compared to adalimumab among adults with moderate-to-severe ulcerative colitis
37. Infliximab Dosing Patterns Among Individuals with Crohnʼs Disease: Results from a Mid-Atlantic Healthplan
38. Assessment of Infliximab Utilization Among Patients with Inflammatory Bowel Disease Across Different Sites of Care
39. Keys to Successful Implementation of Shared Decision Making in Inflammatory Bowel Disease: Recommendations from a Multi-Stakeholder Consensus Panel
40. Novel Statistical Approach to Determine Inflammatory Bowel Disease Patientsʼ Perspectives on Shared Decision Making
41. Efficacy of Adalimumab and Infliximab for the Treatment of Moderate to Severe Ulcerative Colitis: Number Needed to Treat Analysis of Randomized Controlled Trials
42. Gastroenterologistsʼ Views of Shared Decision Making for Patients with Inflammatory Bowel Disease
43. Novel Statistical Approach to Determine Gastroenterologistsʼ Perspectives on Shared Decision Making for Patients with Inflammatory Bowel Disease
44. Direct Health Care Insurer and Out-of-Pocket Expenditures of Inflammatory Bowel Disease: Evidence from a US National Survey
45. Dermatologist–Patient In-Office Discussions of Psoriasis: Focus on Quality of Life
46. The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey
47. The value to patients of reducing lesion severity in plaque psoriasis
48. Self-Reported Adherence, Medication Use, and Switching Patterns among Individuals with Crohnʼs Disease: Data from the National Health and Wellness Survey
49. Frequency and Treatment of Disease Flares among Individuals with Crohnʼs Disease: Data from the National Health and Wellness Survey
50. M1034 The Indirect Costs of Inflammatory Bowel Disease: Evidence From United States National Survey Data
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.